Novartis Ag (NVS) Profit After Tax (QoQ) (2009 - 2024)
Novartis Ag (NVS) Profit After Tax (QoQ) (2009 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -10.19% |
| Sep 30, 2024 | -100.00% |
| Jun 30, 2024 | 247,786,259,441.98% |
| Mar 31, 2024 | 2.34% |
| Dec 31, 2023 | 75.34% |
| Sep 30, 2023 | -100.00% |
| Jun 30, 2023 | 229,405,940,494.06% |
| Mar 31, 2023 | 65.57% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | -100.00% |
| Jun 30, 2022 | 20.55% |
| Mar 31, 2022 | -71.62% |
| Dec 31, 2021 | 254.11% |
| Sep 30, 2021 | -51.68% |
| Jun 30, 2021 | -99.98% |
| Mar 31, 2021 | 1,521,881,413,043,378.00% |
| Dec 31, 2020 | 9.52% |
| Sep 30, 2020 | -100.00% |
| Jun 30, 2020 | 196,526,315,689.47% |
| Mar 31, 2020 | 93.88% |